News
-
-
PRESS RELEASE
BIOVERSYS SUCCESSFULLY COMPLETES ITS IPO AT CHF 36 PER SHARE AND STARTS TRADING ON THE SIX SWISS EXCHANGE TOMORROW, FEBRUARY 07, 2025
BioVersys successfully completes its IPO at CHF 36 per share, listing on SIX Swiss Exchange on February 07, 2025. The biopharmaceutical company focuses on antibacterial products against multidrug-resistant bacteria -
PRESS RELEASE
ALSO invests sustainably in infrastructure - S/4HANA Introduced in Portugal in February
ALSO invests sustainably in infrastructure with the introduction of S/4HANA in Portugal, enhancing efficiency and operational excellence. The state-of-the-art IT ecosystem includes ERP, BI, CRM, WMS, AI, security, data center, and digital platforms -
-
-
PRESS RELEASE
Helvetica announces indicative NAV estimate for end of 2024 in view of IPO of Helvetica Swiss Opportunity Fund on 11 February 2025
Helvetica announces indicative NAV estimate for end of 2024 in view of IPO of Helvetica Swiss Opportunity Fund on 11 February 2025. Fund management discloses NAV ahead of SIX Swiss Exchange listing -
-
-
-
